\Box

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

ſ

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

STATEMENT OF CHANGES IN BENEFICIAL OW

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01 360	tion 30(h)		Investmen	1 001	ipany Act	0119	940							
1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITCI]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Mates Sharon												2	C Directo	r		10% O	wner		
(Last)	(F	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)							- >	C Officer below)	(give title	Other (specify below)		specify		
C/O INTRA-CELLULAR THERAPIES, INC.					03/06/2023								Chairman, President & CEO						
430 EAST 29TH STREET																			
				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. In	6. Individual or Joint/Group Filing (Check Applicable							
(Street)													Line)						
NEW Y	ORK N	IY	10016									X Form filed by One Reporting Person							
P														Form fi Person		re than	One Repo	rting	
(City)	(5	State)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) Date (Month/E			action 2A. Deemed Execution Date, if any (Month/Day/Year)		, Transaction Dispose Code (Instr.		rities Acquired (A) ed Of (D) (Instr. 3, 4			Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount		(A) or (D)	Price	Reported Price (Instr. 3 and 4)				(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
	(e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	e Conversion Date Execution Date, Tr or Exercise (Month/Day/Year) if any C			Co	ansaction ode (Instr.	nsaction Derivative E			6. Date Exercisable and Expiration Date (Month/Day/Year)			itle and A ecurities lerlying ivative Se tr. 3 and 5	curity	8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
						A	mount		(Instr. 4)	ion(s)		1							

Date Exercisable

(2)

(D)

Expiration Date

(2)

Title

Commor

Stock

(1) 03/06/2023 Stock Units

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. On March 6, 2023, the reporting person was granted 122,137 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

122,137

(A)

v

Code

А

Remarks:

Restricted

/s/ Lawrence J. Hineline, Attorney-in-fact

** Signature of Reporting Person

Amount Number of Shares

122,137

\$0.00

03/08/2023

Date

122,137

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.